AstraZeneca's trial illnesses may not be due to COVID-19 shot, Oxford University says




  • In US
  • 2020-09-16 16:17:57Z
  • By Reuters
AstraZeneca
AstraZeneca's trial illnesses may not be due to COVID-19 shot, Oxford University says  

(Reuters) - The adverse events that led to a pause in trials evaluating AstraZeneca Plc's COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.

Enrollment in the British drugmaker's global trials of the vaccine, which it is developing with researchers at Oxford University, was paused on Sept. 6, after a participant in its U.K. trial had a serious side effect thought to be a rare spinal inflammatory disorder called transverse myelitis.

Safety reviews were conducted when volunteers in the trials for testing the vaccine candidate, called AZD1222 or ChAdOx1 nCoV-19, developed unexplained neurological symptoms including changed sensation or limb weakness, and the study was paused while a safety review took place, according to the document. (https://bit.ly/2FDHoEN)

"After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine," the document said.

The vaccine trials have resumed in Britain, Brazil and South Africa, but not yet in the United States.

AstraZeneca and Oxford University did not immediately respond to Reuters requests for comment.


(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur and Shounak Dasgupta)

COMMENTS

More Related News

What you need to know about the coronavirus right now
What you need to know about the coronavirus right now
  • US
  • 2020-09-25 10:16:48Z

The number of novel coronavirus cases in the United States topped 7 million on Thursday - more than 20% of the world's total - as Midwest states reported spikes in COVID-19 infections in September, a Reuters tally shows. All Midwest states except Ohio reported more cases in the past four weeks as compared with the prior four weeks, led by South Dakota and North Dakota. European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US